



September 2, 2016

## **Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016**

WALTHAM, Mass., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the 23<sup>rd</sup> Annual NewsMakers in the Biotech Industry conference in New York on Friday, September 9, 2016 at 1:30 p.m. eastern time.

The presentation will be webcast and accessible through the investor relations section of the Company's web site, <http://ir.minervaneurosciences.com>.

### **About Minerva Neurosciences**

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials in insomnia and major depressive disorder (MDD), respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit [www.minervaneurosciences.com](http://www.minervaneurosciences.com).

Contact:

William B. Boni

VP, Investor Relations/

Corp. Communications

Minerva Neurosciences, Inc.

(617) 600-7376

 [Primary Logo](#)

Source: Minerva Neurosciences, Inc.

News Provided by Acquire Media